why the sell-off?, page-55

yea, im inclined to agree with the comment about 500mil market cap... I think anything over 100mil is being too optimistic

developing commercially successful compounds is very, very difficult, i dont think any other australian biotech company has ever had one (except for peptech)

if you look at history, i'd say of every 100 potentially promising ideas someone comes up with, only 1 makes it on the pharmacy shelves some time later

i think, with so many biochemical pathways in the human body still poorly understood, and many of the "omics" still grappling in the dark, this particular compound has an outside chance of success... best to leave these type of discoveries to the big boys still

just imho, i'd give mpb a target of a quarter of it's market cap a year from now